China rewrites its regulatory framework for stem cell clinical translation.

China’s 2026 reform establishes a new dynamic regulatory architecture for stem cell and advanced biomedical technology translation, using revocable clinical-use authorization and life cycle surveillance.

• Why it matters: The reform addresses the regulatory gap between drug-style approval and technology-based clinical translation, aiming to better balance clinical access with safety oversight and evidence standards.
• What they did: It introduces revocable clinical-use authorization, life cycle surveillance, and mandatory exit as core mechanisms within the new framework for research and translation.
• The result: The approach is designed to align when clinicians can use these technologies with ongoing monitoring and evidentiary validation, moving beyond the drug-versus-technology divide.

AI summary of the abstract · may contain errors · not medical advice · read the paper.